Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
Friday, 3 May 2013
Pivotal Therapeutics' chief scientific officer snags Diamond Jubilee medal for contributions in Canadian biotech field
Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO) has said that its founder, chairman and chief scientific officer, Dr. George Jackowski, was awarded the Queen Elizabeth II Diamond Jubilee Medal earlier this week for his contributions to the Canadian biotech and pharmaceutical industries, by Prime Minister Stephen Harper.
Dr. Jackowski, who is credited for the development of the rapid format cardiac blood test - the standard of care for triaging patients presented to the emergency room with chest pain - was handed the award by the Canadian Prime Minister on April 30 at the Parliament Hill office.
“Pivotal congratulates Dr. Jackowski on his Diamond Jubilee Medal,” said CEO of Pivotal, Eugene Bortoluzzi, in a statement released Thursday. "As one of the pioneers of Canadian Biotech over the past thirty years, his contribution has led to a significant improvement in the quality of life and care for cardiac patients."
The Queen Elizabeth Diamond Jubilee Medal honours significant contributions and achievements by Canadians, and was created by the Government of Canada to mark the 2012 celebrations of the 60th anniversary of Her Majesty Queen Elizabeth II’s accession to the Throne.
Dr. Jackowski, who trained at the Cardiovascular Research Institute at the University of San Francisco, as well as at the Department of Clinical Biochemistry at the University of Toronto, developed the first rapid format cardiac test over 20 years ago, which is currently used worldwide in hospitals and emergency rooms.
The Cardiac Panel point of care test, commonly known as the “cardiac enzymes”, is used to diagnose individuals presenting with chest pain to the emergency room.
His current research focus is on the treatment and prevention of cardiac risk factors, which resulted in the development of Pivotal’s "unique Omega-3 formulation", the company said in its statement, otherwise known as Vascazen, used for the treatment of an Omega-3 dietary deficiency in cardiovascular patients.
"I am extremely honoured to have even been considered for the Diamond Jubilee Medal," says Dr. Jackowski, who has founded 12 biotech companies and has more than 30 years of experience in the cardiovascular disease and central nervous system disease markets.
"The message here is that we always seem to be at the leading edge - one of the pioneers," he adds, referring to the Cardiac Panel test, as well as the company's Vascazen product, and Pivotal's belief that its approach of addressing and correcting an Omega-3 deficiency will become an important part of managing cardiovascular patients.
The company's product, Vascazen, is an FDA-regulated medical food product developed to lower cardiovascular health risks in Omega-3 deficient cardiac patients, including high triglycerides, or fatty substances in the blood that are associated with coronary disease.
The 90 percent-pure product, which was introduced in the U.S. in November 2011, provides those suffering from heart disease with levels of the most important Omega-3 fatty acids in fish oil – EPA and DHA – that the company says are ideal, and cannot be achieved just through simple changes in diet alone.
Vascazen, which avoided the lengthy FDA pre-approval process that is required with drugs, is available with a prescription in all major pharmacies throughout the U.S. Currently, the company's sales reps are focused on the eastern seaboard in the U.S., which contains the highest prevalence of cardiovascular disease-related illness in the nation.